

Stefano Bonora

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6002286/stefano-bonora-publications-by-citations.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

247
papers

4,137
citations

33
h-index

51
g-index

261
ext. papers

4,721
ext. citations

5.4
avg, IF

5
L-index

#	Paper	IF	Citations
247	Identification of 54 mycobacterial species by PCR-restriction fragment length polymorphism analysis of the hsp65 gene. <i>Journal of Clinical Microbiology</i> , 2001 , 39, 2799-806	9.7	118
246	Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients. <i>Journal of Infectious Diseases</i> , 2015 , 211, 178-86	7	114
245	Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. <i>Aids</i> , 2010 , 24, 1064-6	3.5	103
244	An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 662-9	3.2	99
243	Cardiac dysfunction in pauci symptomatic human immunodeficiency virus patients: a meta-analysis in the highly active antiretroviral therapy era. <i>European Heart Journal</i> , 2013 , 34, 1432-6	9.5	94
242	Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. <i>Journal of Infectious Diseases</i> , 2011 , 204, 145-53	7	92
241	Which agents should we use for the treatment of multidrug-resistant Mycobacterium tuberculosis?. <i>Journal of Antimicrobial Chemotherapy</i> , 2004 , 54, 593-602	5.1	88
240	Molecular typing of Mycobacterium bovis strains isolated in Italy from 2000 to 2006 and evaluation of variable-number tandem repeats for geographically optimized genotyping. <i>Journal of Clinical Microbiology</i> , 2009 , 47, 636-44	9.7	85
239	HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007 , 859, 234-40	3.2	77
238	Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. <i>PLoS ONE</i> , 2010 , 5, e13540	3.7	73
237	Association of a single-nucleotide polymorphism in the pregnane X receptor (PXR 63396C->T) with reduced concentrations of unboosted atazanavir. <i>Clinical Infectious Diseases</i> , 2008 , 47, 1222-5	11.6	73
236	Specific mutations in HIV-1 gp41 are associated with immunological success in HIV-1-infected patients receiving enfuvirtide treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 58, 714-22	5.1	68
235	Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 5242-50	5.9	63
234	HPLC-MS method for the quantification of nine anti-HIV drugs from dry plasma spot on glass filter and their long term stability in different conditions. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010 , 52, 774-80	3.5	62
233	High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: a meta-analysis. <i>Atherosclerosis</i> , 2015 , 240, 197-204	3.1	61
232	Cardiovascular disease in HIV patients: from bench to bedside and backwards. <i>Open Heart</i> , 2015 , 2, e000374		56
231	The relationship between nevirapine plasma concentrations and abnormal liver function tests. <i>AIDS Research and Human Retroviruses</i> , 2004 , 20, 716-22	1.6	56

230	A HPLC-MS method for the simultaneous quantification of fourteen antiretroviral agents in peripheral blood mononuclear cell of HIV infected patients optimized using medium corpuscular volume evaluation. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011 , 54, 779-88	3.5	55
229	Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 2976-8	5.9	53
228	Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system. <i>Clinical Pharmacokinetics</i> , 2014 , 53, 891-906	6.2	51
227	Ultrasensitive assessment of residual HIV viraemia in HAART-treated patients with persistently undetectable plasma HIV-RNA: a cross-sectional evaluation. <i>Journal of Medical Virology</i> , 2009 , 81, 400-5	19.7	49
226	Clinical use of lopinavir/ritonavir in a salvage therapy setting: pharmacokinetics and pharmacodynamics. <i>Aids</i> , 2002 , 16, 2081-3	3.5	49
225	Validation of liquid/liquid extraction method coupled with HPLC-UV for measurement of ribavirin plasma levels in HCV-positive patients. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006 , 835, 127-30	3.2	46
224	Lopinavir protein binding in vivo through the 12-hour dosing interval. <i>Therapeutic Drug Monitoring</i> , 2004 , 26, 35-9	3.2	46
223	Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control. <i>Clinical Infectious Diseases</i> , 2015 , 60, 311-7	11.6	41
222	Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. <i>Pharmacogenetics and Genomics</i> , 2010 , 20, 759-65	1.9	38
221	Evaluation of a rapid antigen and antibody combination test in acute HIV infection. <i>Journal of Clinical Virology</i> , 2013 , 57, 84-7	14.5	37
220	Inosine triphosphatase polymorphisms and ribavirin pharmacokinetics as determinants of ribavirin-associate anemia in patients receiving standard anti-HCV treatment. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 165-70	3.2	37
219	Prognostic indicators for recurrent thrombotic events in HIV-infected patients with acute coronary syndromes: use of registry data from 12 sites in Europe, South Africa and the United States. <i>Thrombosis Research</i> , 2014 , 134, 558-64	8.2	36
218	A new assay based on solid-phase extraction procedure with LC-MS to measure plasmatic concentrations of tenofovir and emtricitabine in HIV infected patients. <i>Journal of Chromatographic Science</i> , 2008 , 46, 524-8	1.4	36
217	UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2017 , 138, 223-230	3.5	34
216	Impact of the M184V Resistance Mutation on Virological Efficacy and Durability of Lamivudine-Based Dual Antiretroviral Regimens as Maintenance Therapy in Individuals With Suppressed HIV-1 RNA: A Cohort Study. <i>Open Forum Infectious Diseases</i> , 2018 , 5, ofy113	1	34
215	Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 3061-6	5.1	34
214	Determinants of darunavir cerebrospinal fluid concentrations: impact of once-daily dosing and pharmacogenetics. <i>Aids</i> , 2012 , 26, 1529-33	3.5	33
213	The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. <i>Retrovirology</i> , 2014 , 11, 49	3.6	32

212	Blood brain barrier impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-positive patients. <i>Journal of NeuroVirology</i> , 2016 , 22, 88-92	3.9	31
211	Tenofovir plasma concentrations according to companion drugs: a cross-sectional study of HIV-positive patients with normal renal function. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 1840-1843	5.9	31
210	Maraviroc as intensification strategy in HIV-1 positive patients with deficient immunological response: an Italian randomized clinical trial. <i>PLoS ONE</i> , 2013 , 8, e80157	3.7	31
209	HIV Infection and Primary Prevention of Cardiovascular Disease: Lights and Shadows in the HAART Era. <i>Progress in Cardiovascular Diseases</i> , 2016 , 58, 565-76	8.5	30
208	Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 722-8	3.2	30
207	Comparative safety and efficacy of statins for primary prevention in human immunodeficiency virus-positive patients: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2016 , 37, 3600-3609	8.5	29
206	Influence of CYP2B6 and ABCB1 SNPs on nevirapine plasma concentrations in Burundese HIV-positive patients using dried sample spot devices. <i>British Journal of Clinical Pharmacology</i> , 2012 , 74, 134-40	3.8	29
205	Inpatient and outpatient pharmacokinetic variability of raltegravir in the clinical setting. <i>Therapeutic Drug Monitoring</i> , 2012 , 34, 232-5	3.2	29
204	Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment. <i>Clinical Infectious Diseases</i> , 2008 , 46, 146-7	11.6	29
203	Influence of genotype 3 hepatitis C coinfection on liver enzyme elevation in HIV-1-positive patients after commencement of a new highly active antiretroviral regimen: results from the EPOKA-MASTER Cohort. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2006 , 41, 180-5	3.1	29
202	Pharmacokinetics and pharmacogenetics of anti-tubercular drugs: a tool for treatment optimization?. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 59-82	5.5	28
201	Extra Corporeal Membrane Oxygenation (ECMO) in three HIV-positive patients with acute respiratory distress syndrome. <i>BMC Anesthesiology</i> , 2014 , 14, 37	2.4	25
200	Ribavirin pharmacokinetics and interleukin 28B plus cytochrome P450 27B1 single-nucleotide polymorphisms as predictors of response to pegylated interferon/ribavirin treatment in patients infected with hepatitis C virus genotype 1/4. <i>Hepatology</i> , 2011 , 54, 2278-9	11.2	25
199	Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the IcoNA cohort. <i>Journal of the International AIDS Society</i> , 2019 , 22, e25227	5.4	24
198	High interpatient variability of raltegravir CSF concentrations in HIV-positive patients: a pharmacogenetic analysis. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 241-5	5.1	24
197	Development and validation of a useful HPLC-UV method for quantification of total and phosphorylated-ribavirin in blood and erythrocytes of HCV+ patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2012 , 66, 376-80	3.5	24
196	Even-order aberration cancellation in quantum interferometry. <i>Physical Review Letters</i> , 2008 , 101, 233603	3.4	24
195	Intra-individual variability in lopinavir plasma trough concentrations supports therapeutic drug monitoring. <i>Aids</i> , 2003 , 17, 1107-8	3.5	24

194	Frequent NS5A and multiclass resistance in almost all HCV genotypes at DAA failures: What are the chances for second-line regimens?. <i>Journal of Hepatology</i> , 2018 , 68, 597-600	13.4	23
193	Enfuvirtide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross the placenta. <i>Aids</i> , 2006 , 20, 297-9	3.5	23
192	Unexpected drug-drug interaction between tipranavir/ritonavir and enfuvirtide. <i>Aids</i> , 2006 , 20, 1977-9	3.5	23
191	Co-infection with other respiratory pathogens in COVID-19 patients. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 297-298	9.5	23
190	A simple and sensitive assay for determining plasma tipranavir concentration in the clinical setting by new HPLC method. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007 , 848, 374-8	3.2	22
189	Diagnostic SARS-CoV-2 Cycle Threshold Value Predicts Disease Severity, Survival, and Six-Month Sequelae in COVID-19 Symptomatic Patients. <i>Viruses</i> , 2021 , 13,	6.2	22
188	Efavirenz pharmacogenetics in a cohort of Italian patients. <i>International Journal of Antimicrobial Agents</i> , 2016 , 47, 117-23	14.3	21
187	The ParaSight-F rapid dipstick antigen capture assay for monitoring parasite clearance after drug treatment of Plasmodium falciparum malaria. <i>Transactions of the Royal Society of Tropical Medicine and Hygiene</i> , 1997 , 91, 403-5	2	20
186	Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs. <i>Clinical Pharmacokinetics</i> , 2017 , 56, 355-369	6.2	19
185	A meta-analysis investigating incidence and features of stroke in HIV-infected patients in the highly active antiretroviral therapy era. <i>Journal of Cardiovascular Medicine</i> , 2015 , 16, 839-43	1.9	19
184	Tenofovir and emtricitabine cerebrospinal fluid-to-plasma ratios correlate to the extent of blood-brainbarrier damage. <i>Aids</i> , 2011 , 25, 1437-9	3.5	19
183	A validated high-performance liquid chromatography-ultraviolet method for quantification of the CCR5 inhibitor maraviroc in plasma of HIV-infected patients. <i>Therapeutic Drug Monitoring</i> , 2010 , 32, 86-92	3.2	19
182	Clinical pharmacology of tenofovir clearance: a pharmacokinetic/pharmacogenetic study on plasma and urines. <i>Pharmacogenomics Journal</i> , 2016 , 16, 514-518	3.5	18
181	A UPLC-MS-MS method for the simultaneous quantification of first-line antituberculars in plasma and in PBMCs. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2572-5	5.1	18
180	Intracellular accumulation of ritonavir combined with different protease inhibitors and correlations between concentrations in plasma and peripheral blood mononuclear cells. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 907-10	5.1	18
179	Drug-drug interactions and tolerance in combining antituberculosis and antiretroviral therapy. <i>Expert Opinion on Drug Safety</i> , 2005 , 4, 821-36	4.1	18
178	HIV-1 phenotypic susceptibility to lopinavir (LPV) and genotypic analysis in LPV/r-naive subjects with prior protease inhibitor experience. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003 , 33, 439-47	3.1	18
177	Pharmacokinetics of saquinavir co-administered with cimetidine. <i>Journal of Antimicrobial Chemotherapy</i> , 2002 , 50, 1081-4	5.1	18

176	A LC-MS method to quantify tenofovir urinary concentrations in treated patients. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2015 , 114, 8-11	3.5	17
175	Evaluation of coronary features of HIV patients presenting with ACS: The CUORE, a multicenter study. <i>Atherosclerosis</i> , 2018 , 274, 218-226	3.1	17
174	Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009 , 52, 431-2	3.1	17
173	Clearance of 14-3-3 protein from cerebrospinal fluid heralds the resolution of bacterial meningitis. <i>Clinical Infectious Diseases</i> , 2003 , 36, 1492-5	11.6	17
172	Lower dolutegravir plasma concentrations in HIV-positive patients receiving valproic acid. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 826-827	5.1	16
171	Switching to unboosted atazanavir reduces bilirubin and triglycerides without compromising treatment efficacy in UGT1A1*28 polymorphism carriers. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 2236-42	5.1	16
170	The Longest Persistence of Viable SARS-CoV-2 With Recurrence of Viremia and Relapsing Symptomatic COVID-19 in an Immunocompromised Patient-A Case Study. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofab217	1	16
169	Prevalence and predictors of long corrected QT interval in HIV-positive patients: a multicenter study. <i>Journal of Cardiovascular Medicine</i> , 2017 , 18, 539-544	1.9	15
168	HIV-1 Very Low Level Viremia Is Associated with Virological Failure in Highly Active Antiretroviral Treatment-Treated Patients. <i>AIDS Research and Human Retroviruses</i> , 2015 , 31, 999-1008	1.6	15
167	Prevalence and predictors of blood-brain barrier damage in the HAART era. <i>Journal of NeuroVirology</i> , 2014 , 20, 521-5	3.9	15
166	Magnetic-silica based nucleic acid extraction for Human Immunodeficiency Virus Type-1 drug-resistance testing in low viremic patients. <i>Journal of Clinical Virology</i> , 2010 , 47, 8-12	14.5	15
165	Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev. <i>Antimicrobial Agents and Chemotherapy</i> , 2009 , 53, 2816-23	5.9	15
164	Tipranavir (TPV) genotypic inhibitory quotient predicts virological response at 48 weeks to TPV-based salvage regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 1066-71	5.9	15
163	Elvitegravir/Cobicistat/Tenofovir/Emtricitabine Penetration in the Cerebrospinal Fluid of Three HIV-Positive Patients. <i>AIDS Research and Human Retroviruses</i> , 2016 , 32, 409-11	1.6	15
162	SLC22A2 variants and dolutegravir levels correlate with psychiatric symptoms in persons with HIV. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 1035-1043	5.1	15
161	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. <i>Digestive and Liver Disease</i> , 2017 , 49, 731-741	3.3	14
160	Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 1741-1744	5.1	14
159	Successful pharmacogenetics-based optimization of unboosted atazanavir plasma exposure in HIV-positive patients: a randomized, controlled, pilot study (the REYAGEN study). <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 3096-9	5.1	14

158	Comparative evaluation of seven resistance interpretation algorithms and their derived genotypic inhibitory quotients for the prediction of 48 week virological response to darunavir-based salvage regimens. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 192-200	5.1	14
157	Fatal primary multidrug-resistant tuberculosis in a heart transplant recipient. <i>Transplant International</i> , 1998 , 11, 305-7	3	14
156	Rising temperature and the malaria epidemic in Burundi. <i>Trends in Parasitology</i> , 2001 , 17, 572-3	6.4	14
155	Alpha 1-acid glycoprotein levels in human immunodeficiency virus-infected subjects on antiretroviral regimens. <i>Drug Metabolism and Disposition</i> , 2002 , 30, 859-60	4	14
154	Heart failure in patients with human immunodeficiency virus: a review of the literature. <i>Journal of Cardiovascular Medicine</i> , 2015 , 16, 383-9	1.9	13
153	CNS-Targeted Antiretroviral Strategies: When Are They Needed and What to Choose. <i>Current HIV/AIDS Reports</i> , 2018 , 15, 84-91	5.9	13
152	Raltegravir penetration in seminal plasma of healthy volunteers. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 2744-5	5.9	13
151	Highly active antiretroviral therapy. <i>Lancet, The</i> , 1998 , 351, 1056; author reply 1058-9	40	13
150	Diagnostic accuracy of new and old cognitive screening tools for HIV-associated neurocognitive disorders. <i>HIV Medicine</i> , 2018 , 19, 455	2.7	13
149	Incidence and risk factors for liver enzyme elevation among naive HIV-1-infected patients receiving ART in the ICONA cohort. <i>Journal of Antimicrobial Chemotherapy</i> , 2019 , 74, 3295-3304	5.1	12
148	Dried plasma/blood spots for monitoring antiretroviral treatment efficacy and pharmacokinetics: a cross-sectional study in rural Burundi. <i>British Journal of Clinical Pharmacology</i> , 2015 , 79, 801-8	3.8	12
147	From current status to optimization of HCV treatment: Recommendations from an expert panel. <i>Digestive and Liver Disease</i> , 2016 , 48, 995-1005	3.3	12
146	Intracellular antiviral activity of low-dose ritonavir in boosted protease inhibitor regimens. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 4042-7	5.9	12
145	Interactions between antiretroviral agents and those used to treat tuberculosis. <i>Current Opinion in HIV and AIDS</i> , 2008 , 3, 306-12	4.2	12
144	Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contraindications or intolerance to rifamycins. <i>Journal of Infection</i> , 2008 , 57, 78-81	18.9	12
143	Tenofovir clearance is reduced in HIV-positive patients with subclinical tubular impairment. <i>Aids</i> , 2016 , 30, 915-20	3.5	11
142	Raltegravir penetration in the cerebrospinal fluid of HIV-positive patients. <i>Aids</i> , 2010 , 24, 931-2	3.5	11
141	Antiretroviral activity of pegylated interferon alfa-2a in patients co-infected with HIV/hepatitis C virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2007 , 59, 565-8	5.1	11

140	An improved HPLC fluorimetric method for the determination of enfuvirtide plasma levels in HIV-infected patients. <i>Therapeutic Drug Monitoring</i> , 2006 , 28, 110-5	3.2	11
139	Simultaneous determination of rifampicin and efavirenz in plasma. <i>Therapeutic Drug Monitoring</i> , 2002 , 24, 670-4	3.2	11
138	Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Name for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014. <i>HIV Medicine</i> , 2019 , 20, 99-109	2.7	11
137	Class-specific relative genetic contribution for key antiretroviral drugs. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 3074-9	5.1	10
136	Predominance of hepatitis C virus Q80K among NS3 baseline-resistance-associated amino acid variants in direct-antiviral-agent-naïve patients with chronic hepatitis: single-centre experience. <i>Archives of Virology</i> , 2015 , 160, 2881-5	2.6	10
135	Trends and correlates of HIV-1 resistance among subjects failing an antiretroviral treatment over the 2003-2012 decade in Italy. <i>BMC Infectious Diseases</i> , 2014 , 14, 398	4	10
134	Blood Brain Barrier Impairment in HIV-Positive Name and Effectively Treated Patients: Immune Activation Versus Astrocytosis. <i>Journal of NeuroImmune Pharmacology</i> , 2017 , 12, 187-193	6.9	10
133	Pharmacokinetics of maraviroc administered at 150 mg once daily in association with lopinavir/ritonavir in HIV-positive treatment-naïve patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 1686-8	5.1	10
132	The unbound percentage of saquinavir and indinavir remains constant throughout the dosing interval in HIV positive subjects. <i>British Journal of Clinical Pharmacology</i> , 2002 , 54, 262-8	3.8	10
131	Anti-Xa monitoring improves low-molecular-weight heparin effectiveness in patients with SARS-CoV-2 infection. <i>Thrombosis Research</i> , 2020 , 196, 432-434	8.2	10
130	First-line antiretroviral therapy with efavirenz plus tenofovir disoproxil fumarate/emtricitabine or rilpivirine plus tenofovir disoproxil fumarate/emtricitabine: a durability comparison. <i>HIV Medicine</i> , 2018 , 19, 475	2.7	10
129	Treating HIV Infection in the Central Nervous System. <i>Drugs</i> , 2017 , 77, 145-157	12.1	9
128	Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA $\geq 10^4$ cp/mL. <i>Infection</i> , 2017 , 45, 521-528	5.8	9
127	Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naïve adults. <i>Aids</i> , 2015 , 29, 193-200	3.5	9
126	Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study. <i>International Journal of Pharmaceutics</i> , 2016 , 497, 287-92	6.5	9
125	Pharmacokinetics of the co-administration of boceprevir and St John's wort to male and female healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1911-5	5.1	9
124	Cerebrospinal fluid viral load and neopterin in HIV-positive patients with undetectable viraemia. <i>Antiviral Therapy</i> , 2017 , 22, 539-543	1.6	9
123	Pharmacokinetics of switching unboosted atazanavir coadministered with tenofovir disoproxil fumarate from 400 mg once daily to 200 mg twice daily in HIV-positive patients. <i>Antiviral Therapy</i> , 2011 , 16, 499-504	1.6	9

122	Lack of interaction between raltegravir and cyclosporin in an HIV-infected liver transplant recipient. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 64, 874-5	5.1	9
121	Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2009 , 63, 575-8	5.1	9
120	Microsporidium species in pulmonary cavitary lesions of AIDS patients infected with Rhodococcus equi. <i>Clinical Infectious Diseases</i> , 1997 , 25, 926-7	11.6	9
119	A pilot study on the efficacy, pharmacokinetics and safety of atazanavir in patients with end-stage liver disease. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 1356-64	5.1	9
118	A simple and fast method for quantification of ertapenem using meropenem as internal standard in human plasma in a clinical setting. <i>Therapeutic Drug Monitoring</i> , 2008 , 30, 90-4	3.2	9
117	Clinically significant drug interaction between tipranavir-ritonavir and phenobarbital in an HIV-infected subject. <i>Clinical Infectious Diseases</i> , 2007 , 45, 1654-5	11.6	9
116	Population pharmacokinetic drug-drug interaction pooled analysis of existing data for rifabutin and HIV PIs. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 1330-40	5.1	8
115	Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 409-19	4	8
114	A validated HPLC-MS method for quantification of the CCR5 inhibitor maraviroc in HIV+ human plasma. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014 , 94, 65-70	3.5	8
113	A review of the potential mechanisms of neuronal toxicity associated with antiretroviral drugs. <i>Journal of NeuroVirology</i> , 2020 , 26, 642-651	3.9	8
112	Clearance of cerebrospinal fluid JCV DNA with mirtazapine in a patient with progressive multifocal leukoencephalopathy and sarcoidosis. <i>Antiviral Therapy</i> , 2016 , 21, 633-635	1.6	8
111	Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy. <i>Aids</i> , 2019 , 33, 1256-1260	3.5	8
110	Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015 , 11, 1167-76	5.5	7
109	Local and global spatio-temporal dynamics of HIV-1 subtype F1. <i>Journal of Medical Virology</i> , 2014 , 86, 186-92	19.7	7
108	Effect of raltegravir on the total and unintegrated proviral HIV DNA during raltegravir-based HAART. <i>Antiviral Therapy</i> , 2011 , 16, 797-803	1.6	7
107	Pharmacokinetics of the raltegravir/maraviroc/etravirine combination. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 1932-4	5.1	7
106	Fatal pneumothorax complicating BAL in a bone marrow transplant recipient with bronchiolitis obliterans. <i>Chest</i> , 1997 , 111, 1468-9	5.3	7
105	Detection of stavudine concentrations in plasma of HIV-infected patients taking zidovudine. <i>Aids</i> , 2004 , 18, 577-8	3.5	7

104	Response of uncomplicated falciparum malaria to oral chloroquine and quinine in Burundi highlands. <i>Acta Tropica</i> , 1998 , 70, 25-33	3.2	7
103	Efficacy, tolerability and virological consequences of long-term use of unboosted atazanavir plus 2 NRTIs in HIV-infected patients. <i>Current HIV Research</i> , 2014 , 12, 339-46	1.3	7
102	Raltegravir Plus Nevirapine as Maintenance Antiretroviral Therapy in HIV-Positive Patients: Safety, Efficacy and Pharmacokinetics. <i>Current HIV Research</i> , 2016 , 14, 54-60	1.3	7
101	Presence of Epstein-Barr virus DNA in cerebrospinal fluid is associated with greater HIV RNA and inflammation. <i>Aids</i> , 2020 , 34, 373-380	3.5	7
100	Pre-existent NRTI and NNRTI resistance impacts on maintenance of virological suppression in HIV-1-infected patients who switch to a tenofovir/emtricitabine/rilpivirine single-tablet regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 855-865	5.1	7
99	Zika virus infection in two travelers returning from an epidemic area to Italy, 2016: Algorithm for diagnosis and recommendations. <i>Travel Medicine and Infectious Disease</i> , 2016 , 14, 506-508	8.4	6
98	Effect of ABCC2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations. <i>Journal of Clinical Pharmacology</i> , 2018 , 58, 1550-1556	2.9	6
97	Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients. <i>Antiviral Research</i> , 2014 , 108, 44-7	10.8	6
96	Voriconazole and atazanavir: a CYP2C19-dependent manageable drug-drug interaction. <i>Pharmacogenomics</i> , 2014 , 15, 1281-6	2.6	6
95	Raltegravir: is a 400 mg once-daily dose enough?. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 595-75.1	5.1	6
94	Phase control of a path-entangled photon state by a deformable membrane mirror. <i>Journal of the Optical Society of America B: Optical Physics</i> , 2010 , 27, A175	1.7	6
93	Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 384-7	5.1	6
92	Recovery of long-term natural protection against reactivation of CMV retinitis in AIDS patients responding to highly active antiretroviral therapy. <i>Journal of Infection</i> , 1999 , 39, 193-7	18.9	6
91	On the SARS-CoV-2 "Variolation Hypothesis": No Association Between Viral Load of Index Cases and COVID-19 Severity of Secondary Cases. <i>Frontiers in Microbiology</i> , 2021 , 12, 646679	5.7	6
90	Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 812-815	5.1	6
89	Older Age is Associated with Higher Dolutegravir Exposure in Plasma and Cerebrospinal Fluid of People Living with HIV. <i>Clinical Pharmacokinetics</i> , 2021 , 60, 103-109	6.2	6
88	An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project. <i>New Microbiologica</i> , 2015 , 38, 443-90	1.1	6
87	Efficacy, safety and pharmacokinetics of atazanavir (200mg twice daily) plus raltegravir (400mg twice daily) dual regimen in the clinical setting. <i>Journal of Clinical Virology</i> , 2017 , 87, 30-36	14.5	5

86	Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics. <i>Pharmacogenomics</i> , 2017 , 18, 865-880	2.6	5
85	PrEP in Italy: The time may be ripe but who's paying the bill? A nationwide survey on physicians' attitudes towards using antiretrovirals to prevent HIV infection. <i>PLoS ONE</i> , 2017 , 12, e0181433	3.7	5
84	The outcome of HIV-positive late presenters according to detectable CMV DNA and anti-CMV treatment. <i>Antiviral Therapy</i> , 2018 , 23, 451-456	1.6	5
83	Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 3163-3166	5.1	5
82	Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy. <i>PLoS ONE</i> , 2015 , 10, e0124252	3.7	5
81	Low rate of virological failure and maintenance of susceptibility to HIV-1 protease inhibitors with first-line lopinavir/ritonavir-based antiretroviral treatment in clinical practice. <i>Journal of Medical Virology</i> , 2010 , 82, 1996-2003	19.7	5
80	Ketoconazole and lopinavir/ritonavir coadministration: boosting beyond boosting. <i>AIDS Research and Human Retroviruses</i> , 2003 , 19, 941-2	1.6	5
79	Treating advanced HIV infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003 , 34, 344-351	5.1	5
78	Rapid absorption and clinical effectiveness of intragastric mefloquine in the treatment of cerebral malaria in African children. <i>Journal of Antimicrobial Chemotherapy</i> , 1999 , 44, 573-6	5.1	5
77	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 628-639	5.1	5
76	Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases. <i>Lancet Infectious Diseases</i> , 2021 , 21, 914-915	25.5	5
75	Real life experiences in HCV management in 2018. <i>Expert Review of Anti-Infective Therapy</i> , 2019 , 17, 117-138	5.3	5
74	The clinical pharmacology of integrase inhibitors. <i>Expert Review of Clinical Pharmacology</i> , 2019 , 12, 31-44	5.8	5
73	Cerebral white matter Hyperintensities in HIV-positive patients. <i>Brain Imaging and Behavior</i> , 2020 , 14, 10-18	4.1	5
72	Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 1436-9	5.1	4
71	Cytomegalovirus central nervous system compartmentalization in a patient presenting with AIDS. <i>Antiviral Therapy</i> , 2015 , 20, 357-9	1.6	4
70	Detectable cerebrospinal fluid JCV DNA in late-presenting HIV-positive patients: beyond progressive multifocal leukoencephalopathy?. <i>Journal of NeuroVirology</i> , 2017 , 23, 763-767	3.9	4
69	Acute HIV infection: improved algorithms for HIV testing. <i>Journal of Clinical Virology</i> , 2015 , 63, 51-2	14.5	4

68	Experimental evaluation of a new system for laser tissue welding applied on damaged lungs. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2013 , 16, 577-82	1.8	4
67	Pharmacokinetics and safety of the co-administration of the antiretroviral raltegravir and the lipid-lowering drug ezetimibe in healthy volunteers. <i>Journal of Antimicrobial Chemotherapy</i> , 2011 , 66, 885-9	5.1	4
66	Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice. <i>PLoS ONE</i> , 2016 , 11, e0160761	3.7	4
65	Continuous intravenous infusion of enfuvirtide in a patient with a multidrug-resistant HIV strain. <i>International Journal of Clinical Pharmacy</i> , 2016 , 38, 749-51	2.3	4
64	Use of Daclatasvir in HCV/HIV-Coinfected Patients in a Real-Life Setting. <i>AIDS Reviews</i> , 2017 , 19, 24-34	1.5	4
63	Pharmacokinetics of first-line antitubercular drugs in plasma and PBMCs. <i>British Journal of Clinical Pharmacology</i> , 2017 , 83, 1146-1148	3.8	3
62	Is the rate of virological failure to cART continuing to decline in recent calendar years?. <i>Journal of Clinical Virology</i> , 2019 , 116, 23-28	14.5	3
61	Socioeconomic status and biomedical risk factors in migrants and native tuberculosis patients in Italy. <i>PLoS ONE</i> , 2017 , 12, e0189425	3.7	3
60	HCV NS3 naturally occurring variants in HIV/HCV coinfecting DAA-naïve patients: consideration for HCV genotyping resistance testing. <i>Infection</i> , 2016 , 44, 789-792	5.8	3
59	Cerebrospinal fluid biomarkers in patients with plasma HIV RNA below 20 copies/mL. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19719	5.4	3
58	Disappearance of renal stones in an HIV-1-infected patient after reduction of atazanavir dose. <i>AIDS Research and Human Retroviruses</i> , 2014 , 30, 835-6	1.6	3
57	Pharmacokinetics of 400 mg of raltegravir once daily in combination with atazanavir/ritonavir plus two nucleoside/nucleotide reverse transcriptase inhibitors. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 482-4	5.1	3
56	Tuberculosis among refugees and displaced people at the Burundi-Rwanda border. <i>Clinical Infectious Diseases</i> , 1998 , 26, 500-1	11.6	3
55	Failure of prophylaxis against PCP in patients with HIV infection. <i>AIDS Patient Care and STDs</i> , 1998 , 12, 843-8	5.8	3
54	Healthy ranges for alanine aminotransferase levels. <i>Annals of Internal Medicine</i> , 2003 , 138, 156-7; author reply 156-7	8	3
53	Pharmacokinetic evaluation of indinavir and indinavir/ritonavir-containing antiretroviral regimens in a clinical setting. <i>Therapeutic Drug Monitoring</i> , 2002 , 24, 574-6	3.2	3
52	Dual antiretroviral therapies are effective and safe regimens in the central nervous system of neurologically symptomatic people living with HIV. <i>Aids</i> , 2020 , 34, 1899-1906	3.5	3
51	Blood-Brain Barrier Impairment in Patients Living with HIV: Predictors and Associated Biomarkers. <i>Diagnostics</i> , 2021 , 11,	3.8	3

50	In-hospital and long-term outcomes of HIV-positive patients undergoing PCI according to kind of stent: a meta-analysis. <i>Journal of Cardiovascular Medicine</i> , 2019 , 20, 321-326	1.9	3
49	Tenofovir disoproxil fumarate discontinuation for renal outcomes: any room for treatment personalization?. <i>Pharmacogenomics Journal</i> , 2019 , 19, 65-71	3.5	3
48	Pharmacogenetic determinants of kidney-associated urinary and serum abnormalities in antiretroviral-treated HIV-positive patients. <i>Pharmacogenomics Journal</i> , 2020 , 20, 202-212	3.5	3
47	Antiretroviral therapy in chronic liver disease: focus on HIV/HCV coinfection--statements of the First Italian Consensus Workshop. <i>AIDS Reviews</i> , 2005 , 7, 161-7	1.5	3
46	A probable drug-to-drug interaction between voriconazole and haloperidol in a CYP2C19 poor metabolizing patient. [corrected]. <i>Infezioni in Medicina</i> , 2015 , 23, 367-9	3.6	3
45	Trichinella britovi outbreak in Piedmont, North-West Italy, 2019-2020: Clinical and epidemiological insights in the one health perspective.. <i>Travel Medicine and Infectious Disease</i> , 2022 , 47, 102308	8.4	3
44	The "milky way" galaxy of HIV-related central nervous system immune reaction syndromes. <i>Journal of NeuroVirology</i> , 2019 , 25, 887-892	3.9	2
43	Undetectable antimicrobial plasma concentrations in an HIV-positive patient with protein-losing enteropathy and chylothorax during Mycobacterium genavense and Leishmania abdominal infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 546-548	5.1	2
42	Cerebrospinal fluid abacavir concentrations in HIV-positive patients following once-daily administration. <i>British Journal of Clinical Pharmacology</i> , 2018 , 84, 1380-1383	3.8	2
41	Peripheral and cerebrospinal fluid immune activation and inflammation in chronically HIV-infected patients before and after virally suppressive combination antiretroviral therapy (cART). <i>Journal of NeuroVirology</i> , 2018 , 24, 679-694	3.9	2
40	Elimination half-life may explain the relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. <i>Clinical Infectious Diseases</i> , 2013 , 56, 1677-8	11.6	2
39	Rilpivirine Pharmacokinetics in 3 HIV-Positive Patients With Liver Cirrhosis Concomitantly Receiving Pantoprazole. <i>Therapeutic Drug Monitoring</i> , 2015 , 37, 695-6	3.2	2
38	Comment on "Higher CNS penetration-effectiveness of long-term combination antiretroviral therapy is associated with better HIV-1 viral suppression in cerebrospinal fluid". <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013 , 62, e118-9	3.1	2
37	Efficacy of early pegylated interferon alpha-2b monotherapy for acute hepatitis C in HIV-infected patients. <i>Clinical Infectious Diseases</i> , 2009 , 48, 1636-7	11.6	2
36	Detection of low-frequency K103N mutants after unstructured discontinuation of efavirenz in the presence of the CYP2B6 516 TT polymorphism. <i>Journal of Antimicrobial Chemotherapy</i> , 2008 , 62, 1188-90	5.1	2
35	Lopinavir measurement in pleural effusion in a human immunodeficiency virus type 1-infected patient with kaposi's sarcoma. <i>Antimicrobial Agents and Chemotherapy</i> , 2002 , 46, 3684-5	5.9	2
34	Molecular typing of Mycobacterium tuberculosis. <i>Lancet, The</i> , 1999 , 353, 1442	4.0	2
33	Clinical Phenotype and Contagiousness of Early Breakthrough SARS-CoV-2 Infections after BNT162b2 COVID-19 mRNA Vaccine: A Parallel Cohort Study in Healthcare Workers.. <i>Vaccines</i> , 2021 , 9,	5.3	2

32	Validation of a UHPLC-MS/MS Method to Quantify Twelve Antiretroviral Drugs within Peripheral Blood Mononuclear Cells from People Living with HIV. <i>Pharmaceuticals</i> , 2020 , 14,	5.2	2
31	Low Tenofovir Plasma Exposure in HIV Oral Pre-exposure Prophylaxis Recipients with Gastrointestinal Disorders. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 ,	5.9	2
30	The impact of age on antiretroviral drug pharmacokinetics in the treatment of adults living with HIV. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2021 , 17, 665-676	5.5	2
29	HIV-1 detection in the olfactory mucosa of HIV-1-infected participants. <i>Aids</i> , 2019 , 33, 665-674	3.5	2
28	Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	2
27	Safety and efficacy of daclatasvir at doses other than 60 mg daily in HIV/HCV co-infected subjects: Data from the ICONA/HepalCONA foundation cohorts. <i>Digestive and Liver Disease</i> , 2020 , 52, 447-451	3.3	1
26	An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19771	5.4	1
25	Durability of lopinavir/ritonavir dual-therapies in individuals with viral load . <i>Journal of the International AIDS Society</i> , 2014 , 17, 19799	5.4	1
24	Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice. <i>Journal of the International AIDS Society</i> , 2014 , 17, 19571	5.4	1
23	Seminal pharmacokinetics and antiviral efficacy of once-daily maraviroc plus lopinavir/ritonavir in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 2586-8	5.1	1
22	No pharmacokinetic interaction between raltegravir and amlodipine: importance for co-prescribing in ageing HIV-infected individuals. <i>Aids</i> , 2014 , 28, 1993-5	3.5	1
21	No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy. <i>Journal of Medical Virology</i> , 2011 , 83, 391-8	19.7	1
20	Is peritoneal fluid a sanctuary site for HIV?. <i>Journal of Antimicrobial Chemotherapy</i> , 2010 , 65, 2052-3	5.1	1
19	Clinical validation and applicability of different tipranavir/ritonavir genotypic scores in HIV-1 protease inhibitor-experienced patients. <i>Current HIV Research</i> , 2009 , 7, 425-33	1.3	1
18	Ritonavir-dependent fluconazole boosting of nelfinavir: a report of three cases. <i>Journal of Antimicrobial Chemotherapy</i> , 2006 , 58, 483-5	5.1	1
17	Mycobacterium tuberculosis transmission and HIV status. <i>Lancet, The</i> , 2000 , 355, 2077; author reply 2078	4.0	1
16	Granulomatous inflammation and transmission of infectious disease. <i>Trends in Immunology</i> , 1999 , 20, 337-8		1
15	High Incidence of Infections in HIV-positive Patients Treated for Lymphoproliferative Disorders. <i>Current HIV Research</i> , 2017 , 15, 258-265	1.3	1

14	Medication burden and clustering in people living with HIV undergoing therapeutic drug monitoring. <i>British Journal of Clinical Pharmacology</i> , 2021 , 87, 4432-4438	3.8	1
13	Pharmacokinetics of an antiretroviral regimen in a patient unable to swallow solid oral dosage forms. <i>American Journal of Health-System Pharmacy</i> , 2016 , 73, 750-4	2.2	1
12	Tenofovir Alafenamide and Tenofovir Disoproxil Fumarate are not transported by Concentrative Nucleoside Transporter 2. <i>Diagnostic Microbiology and Infectious Disease</i> , 2019 , 94, 202-204	2.9	1
11	Early low-molecular-weight heparin administration is associated with shorter time to SARS-CoV-2 swab negativity. <i>Antiviral Therapy</i> , 2020 , 25, 327-333	1.6	1
10	Patterns of Cerebrospinal Fluid Alzheimer's Dementia Biomarkers in People Living with HIV: Cross-Sectional Study on Associated Factors According to Viral Control, Neurological Confounders and Neurocognition.. <i>Viruses</i> , 2022 , 14,	6.2	1
9	Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor-Based Regimen: The "STORE" Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020 , 84, 290-294	3.1	0
8	Does iatrogenic scleroderma due to injection-site reaction to enfuvirtide impair absorption of the drug?. <i>Clinical Drug Investigation</i> , 2008 , 28, 305-11	3.2	0
7	Rifampicin and Isoniazid Maximal Concentrations are Below Efficacy-associated Thresholds in the Majority of Patients: Time to Increase the Doses?. <i>International Journal of Antimicrobial Agents</i> , 2021 , 57, 106297	14.3	0
6	Enhancing care for people living with HIV: current and future monitoring approaches. <i>Expert Review of Anti-Infective Therapy</i> , 2021 , 19, 443-456	5.5	0
5	Intrapulmonary concentrations of cefepime. <i>Critical Care Medicine</i> , 2004 , 32, 1238; author reply 1238-9	1.4	
4	Screening Accuracy of Mini Addenbrooke's Cognitive Examination Test for HIV-Associated Neurocognitive Disorders in People Ageing with HIV.. <i>AIDS and Behavior</i> , 2022 , 1	4.3	
3	Good times, bad times: A diary of a physician in the COVID-19 era. <i>European Journal of Internal Medicine</i> , 2020 , 77, 132-133	3.9	
2	Optimizing HIV therapy. A consensus project on differences between cytidine analogues and regime compactness. <i>New Microbiologica</i> , 2014 , 37, 285-306	1.1	
1	Determinants of SARS-CoV-2 Contagiousness in Household Contacts of Symptomatic Adult Index Cases.. <i>Frontiers in Microbiology</i> , 2022 , 13, 829393	5.7	